Introduction
Only 10% of patients presenting in the emergency department with maintained precordial pain show an elevation in the ST segment of an electrocardiogram. In acute coronary ischaemia processes other than infarction with an elevated ST segment (non-Q infarction or without a fall in the ST, unstable angina and unidenti® ed ischaemia), the use of biochemical markers may be the only criteria to diagnose myocardial necrosis and in some cases to establish the prognosis.
For many years, the enzymatic pro® le (creatine kinase, CK-MB isoenzyme activity, aspartate aminotransferase , lactate dehydrogenase ) has been the biochemical method of choice i the diagnosis of acute myocardial infarction (AMI). Indeed, the World Health Organization (WHO) continues to use the catalytic CK-MB activity and creatine kinase in the diagnosis of AMI [1] .
In the 1990s, more sensitive and speci® c cardiac markers have been developed to detect this diseases. A coronary ischaemia marker must ful® l the following characteristics: (1) a simple methodology providing rapid results 24 h a day; (2) a high diagnostic sensitivity, specially during the ® rst 24 h of the ischaemic process; and (3) diagnostic speci® city as close to 100% as possible. The following markers were used: serum myoglobin, CK-MB isoforms, CK-MB protein concentration (CK-MB mass), and troponins I and T. Each marker has pros and cons with respect to others and there is no consensus about the ideal marker. Myoglobin is the earliest marker and is highly sensitive in the diagnosis of the disease within 2 h of precordial pain [2, 3] . However, its diagnostic speci® city is poor. The CK-MB isoforms are very early markers with good sensitivity within 4± 6 h of precordial pain with relatively high speci® city [4] . However, the technology used to perform this method is complicated [5] and expensive [6] . Protein concentration of CK-MB has markedly improved the analytical speci® city and sensitivity of the activity of CK-MB methods [7, 8] . CK-MB mass has a high diagnostic sensitivity 4± 6 h after precordial pain and remains increased for the ® rst 48 h. The cardiospeci® city of troponin [9] together with its wide diagnostic window (elevations persist in plasma from 6± 12 h to 5± 10 days for troponin I and from 6± 12 h to 5± 15 days for troponin T) have revolutionized the diagnosis of coronary ischaemia in the last few years [10± 13].
In the 2000s, the Joint Committee of the European Society of Cardiology and the American College of Cardiology established rede® ned criteria to classify acute coronary syndromes [14] and they proposed troponin and CK-MB mass as biochemical markers of myocardial necrosis. Recently, Apple and Wu [15] stated that cardiac troponin is the best marker for diagnosis, risk strati® cation and guidance of therapy in acute coronary syndromes.
The correct choice of a cardiac marker according to the time of evolution of the ischaemic process is, currently, controversial, and the scienti® c societies are attempting to protocolize this choice [ 16± 18] . The lack of method standarization [19, 20] , specially measuring troponin, has made it diae cult to compare the results and choose the best method [21] . In fact, scienti® c societies are, at present, elaborating primary [22] and reference materials [23] for cardiac markers, with the aim of achieving the transferability of results and establishing the diagnostic limits to facilitate the clinical use of these markers. The National Academy of Clinical Biochemistry (NACB) has suggested that two cutoå values for the troponins be used, one indicative of AMI and the other indicative of cardiac injury [17] . Accurate discrimination between minor myocardial injury versus analytical imprecision requires high interassay precision at the low cutoå values. Thus, the NACB has recommended a precision for cardiac troponin assays of µ10% [17] .
Therefore, each laboratory should evaluate its methods, especially with troponin I, and establish its reference ranges and cutoå values as well as the clinical sensitivity and speci® city for the diå erent processes of acute coronary ischaemia [21] . In the present study, we performed an analytical evaluation of two new methods to measure the protein concentration of CK-MB mass and cardiac troponin I using the Dimension RxL automatic analyser (Dade Behring, Newark, DE, USA).
Materials and methods

Patients
We investigated 37 patients with con® rmed AMI admitted to the coronary care unit (CCU). The de® nitive diagnosis of AMI required, at least, two of the following three clinical criteria proposed by the WHO [1] : typical prolonged severe chest pain of > 20-min duration, the evolution of abnormal Q waves or equivalents on serial ECGs, and serial CK and CK-MB elevations with an initial rise and subsequent fall peak. Twenty patients with a clinical diagnosis compatible with unstable angina were included in the study. Blood was withdrawn at diå erent time intervals after precordal pain.
Reference values were calculated from 50 samples obtained from apparently normal people free of cardiological diseases sent to our laboratory for analytical control before minor surgical interventions.
To study the cross-reactivity of the methods, samples of myocardial, brain and skeletal muscle (biceps, quadriceps) from a subject were obtained at autopsy 20 h after death. The patient had died in an accident. Ethical permission for tissue donation was previously obtained. Samples were frozen at ± 80 8C until their analyses.
Analytical methods
. Troponin I (cat. no. RF421; Dade Behring). The immunoassay was based on the sandwich principle with two monoclonal antibodies binding to a conjugate reagent composed with alkaline phosphatase . The coloured ® nal product absorbed at 510 nm. . Protein concentration of CK-MB (CK-MB mass) (cat. no. RF420; Dade Behring). The immunoassay was based on the sandwich principle with a monoclonal antibody speci® c for MB isoenzyme and another against the B subunit of creatine kinase. The detection system is b-galactosidase. . Catalitic activity of CK-MB (cat. no. DF31; Dade Behring). The immunoinhibition method detected the B subunit of creatine kinase. . Creatine kinase activity (CK) (cat. no. DF29A; Dade Behring). The assays were carried out in an automatic analyser Dimension RxL.
Analytical evaluation of the methods
The analytical intervals of the methods were evaluated following the directions of the Socite¨Franc°aise de Biologie Clinique [24] . To calculate the analytical interval, nine standard aqueous solutions of troponin I (cardiac troponin I calibrator; Dade Behring cat. no. RC421B) ranging from 0.1 to 60 mg l ± 1 and of CK-MB (mass creatine kinase MB isoenzyme calibrator Dade Behring cat. no. RC420) (1± 400 mg l ± 1 ) were used. The recommendations of the European Committee for Clinical Laborator y Standards (ECCLS) were followed for the study of the imprecision and inaccuracy of the method [25] . Control serums of 0.34, 0.68, 2.42, 9.7 and 22.6 mg l ± 1 troponin I and 2, 4.9, 7.5, 15.1 and 42.6 mg l ± 1 CK-MB mass were used.
To determine the analytical recovery of the methods, increasing the quantities of troponin I to CK-MB mass were added to diå erent aliquots of sera pool. A total of 20, 30 and 40 mg l ± 1 troponin I and 50, 100 and 200 mg l ± 1
CK-MB mass were the standard aqueous solutions used. The dilution eå ect was corrected by adding the same volume of saline solution to unaltered samples.
The reference values of the methods were obtained following the recommendations of the Panel of Experts of the IFCC on reference values [26] .
Tissue speci¢city of the methods
Cross-reactivity for CK-MB mass method was carried out with homogenates from myocardial, brain and skeletal muscle tissue. The crude extracts preparation was performed following the previous protocol used for myocardial tissue [27, 28] . Tissue was homogenized in 2 vols 50 mmol l ± 1
Tris-HCl buå er, pH 8.0, containing 2 mmol l ± 1 2-mercaptoethano l with a Polytron ATA 20 TSM homogenizer (Kinematica Gmb, Littau, Switzerland). Homogenization was carried out in an ice bath at 4 8C for 45 min. After centrifugation of the homogenate at 4000g for 15 min in a Beckman J2-21 centrifuge (Beckman Instruments, Palo Alto, CA, USA), the supernatant was collected and ® ltered. The protein concentration of CK-MB and the catalytical activity of total creatine kinase were measured in the supernatant.
The cardiospeci® city of troponin was veri® ed using myocardial and skeletal muscle (quadriceps, biceps) tissue. Troponin I was measured in myo® brillar and cytosolic fractions of these tissues. To separate these fractions, the protocol of Katus et al. was applied [29] . The tissue was homogenized in a buå er (50 mmol l ± 1 Tris-HCl, 2 mmol l ± 1 EDTA, 0.05 mmol l ± 1 dithiotreitol, pH 7.0) and stirred at 4 8C for 1 h. The insoluble molecules were precipitated by ultracentrifugatio n for 1 h at 100 000g (4 8C). The pellet was washed and centrifugation was repeated. The troponins contained in the myo® brillar fraction were extracted by homogenization of the precipitate for 1 h at 4 8C in a solution composed by 0.4 mol l ± 1 potassium chloride, 0.01 mol l ± 1 magnesium chloride, 0.1 mol l ± 1 potassium dihydrogen phosphate, 0.05 mol l ± 1 potassium monohydroge n phosphate, 0.04 mol l ± 1 sodium pyrophosphate , pH 7.0. The solubilized troponin complex was separated from actomyosin by centrifugation for 1 h at 20 000g at 4 8C. Troponin I concentration was measured in the myo® brillar and soluble fractions as well as in the myocardial and skeletal muscle homogenates. The protein content was measured by a pirogallol red method [30] .
Diagnostic decision limits
The decision limits for the markers were obtained using receiver operating characteristic (ROC) curves.
Statistical methods
Mean, SD and coeae cient of variation for studying the accuracy and imprecision were used. Analytical intervals were determined by regression analyses. The Mann± Whitney U-test was applied to establish the statistical diå erences between groups. To calculate the reference values of the method, the 2.5, 50 and 97.5 percentiles were used. ROC curves were applied to obtain the cutoå values. Con® dence intervals (95%) of sensitivities were calculated non-parametrically . The À 2 -test was used to compare the percentages of sensitivity.
Results
Analytical interval of methods
The analytical interval for CK-MB mass ranged from 0.1 to 341 mg l ± 1 . Figure 1 shows the linear regression of the least-squares ( yˆ0:978x ‡ 0:24; rˆ0:999) established among the theoretical values of the CK-MB standards processed in triplicate over 3 consecutive days, and the values found. The analytical interval for troponin I was 0.05± 50 mg l ± 1 (® gure 2). 
Imprecision and inaccuracy
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Reference values
The reference values for the cardiac markers studied are contained in table 7. Statistical diå erences between men and women groups were not found for any marker: troponin I (p > 0:05), CK-MB mass (p > 0:05), CK-MB mass/total CK (p > 0:05). Thus, the reference values were established in the total population.
Crossreactivity
The CK-MB mass method showed the absence of crossreactivity with CK-BB and CK-MM. CK-MB concentration in myocardial extract was similar before and after the addition of 1500 U l ± 1 CK-BB from brain tissue or to 12 000 U l ± 1 CK-MM from skeletal muscle tissue (® gure 3). The absence of troponin I in skeletal muscle was corroborated: the concentration of troponin I in biceps and quadriceps was not detected (< 1% of the values obtained in myocardial tissue). The troponin I concentration in the myo® brillar fraction of cardiac tissue was 7.2 mg g ± 1 protein and only 4% of total troponin content was found in the soluble fraction (® gure 4). 
Diagnostic decision limits
ROC curves were applied to establish the diagnostic decision limits of the methods. Table 8 shows the percentages of sensitivity of troponin I for cardiac markers in AMI using the cutoå values that established (0.228 and 0.77 mg l ± 1
) and the cutoå value proposed by the manufacture r (1.5 mg l ± 1 ). In the early 6 h of precordial pain, the sensitivity of troponin I, using the reference value (0.228 mg l ± 1 ) as a cutoå , was similar to CK-MB mass (À 2ˆ0 :82, p > 0:05). However, the sensitivities of troponin I using 0.77 and 1.5 mg l ± 1 were lower and signi® cantly diå erent than CK-MB mass (À 2ˆ1 2, p < 0:01; and À 2ˆ3 4, p < 0:001, respectively). After 7 h of precordial pain, the sensitivity was reliable using any cutoå value. Table 9 contains the percentage of patients with unstable angina and the increase of cardiac marker values. No diå erences were found (p > 0:05) between the percentages of sensitivity for troponin I using 0.228, 0.77 or 1.5 mg l ± 1 as the cutoå . The sensitivity for CK-MB mass was lower than troponin I (p < 0:05) to diagnose minimum myocardial damage.
Discussion
The CK-MB mass method presented demonstrates good analytical precision for concentrations with clinical pathological signi® cance of the isoenzyme. However, the variation coeae cient within the normal limits is > 10%, similar to that obtained by other authors for other CK-MB mass methods [31] . At levels that were slightly higher than our reference 0.34 mg l ± 1 , we found analogically variation coeae cients of 11.2% for the troponin I method. Nonetheless, > 0.68 mg l ± 1 , the imprecision of the assay is < 5% with the variation coeae cient obtained being better than that reported for other commercially available troponin tests [16, 21] . More- A. Galán et al. Measurements of blood CK-MB mass and troponin I over, the response time for the measurement of these markers is < 20 min, ful® lling the norms proposed by the International Society of Enzymology [32] for cardiac marker response time and is therefore compatible with the results required in emergency department laboratories [17] .
On the study of CK-MB cross-reactivity, we found that contrary to methods analysing the catalytic activity of CK-MB, the monoclonal antibody used in our CK-MB mass method exclusively recognized the MB isoenzyme and not the BB and MM isoenzymes of creatine kinase. This method, therefore, improves the metrologic speci® -city of the assay with regard to activity, although the CK-MB mass is not 100% cardiospeci® c. The skeletal muscle contains small, but signi® cant, quantities (1± 3%) of the isoenzyme [33] and, thus, following massive musculoskeletal lesions, this marker is elevated [34] . We have also shown that the troponin I method evaluated herein lacks cross-reactivity with human skeletal muscle (biceps, quadriceps). , which are higher than those proposed by the manufacturer (0± 0.05 mg l ± 1 ). The diå erences between the reference value of the diå erent assays in the market may range to up to 10-fold [12, 21, 35, 36] . The choice of a cutoå point is one of the most widely debated subjects [17, 37± 40] . From our results, it may be seen that the cutoå point of 1.5 mg l ± 1 proposed by the manufacturer of the assay evaluated provides a diagnostic sensitivity of only 22% for AMI during the ® rst 6 h of the ischaemic process. Moreover, the detection of the small myocardial lesions with this cutoå point is lower than that found when using the diagnostic cutoå values we have established, although the diå erence is not signi® cant. The best sensitivity for the diagnosis of AMI is that obtained with 0.228 mg l ± 1 (88% in the ® rst 6 h of the ischaemic process). However, the imprecision of the method is > 10% at this concentration. Therefore, although sensitivity is lost at 0.77 mg l ± 1 , since it is of 44.4% in the ® rst 6 h of the pain, the reliability of the method is much greater at these levels. Moreover, according to our results, the sensitivity of the marker for the small myocardial lesions is similar if either 0.228 or 0.77 mg l ± 1 are used as the diagnostic cutoå value. Nonetheless, our results agree with the criteria of many authors [17, 18, 41] in that to obtain the true diagnostic value of troponin I, > 6 h of the ischaemic process must go by. In fact, it is after 7 h that our results show a diagnostic sensitivity of 100% for AMI. The late appearance of troponin in blood may be due to its profound cellular localization since the 94% of troponin T and the 97% of troponin I are largely bound to the tropomyosin complex and only the remaining 6 and 3%, respectively, are found in the cytoplasm. In our study with cardiac tissue, we only detected 4% of troponin I in the soluble fraction in tissue. The wide diagnostic window of troponin (10± 15 days) may be due to its profound localization. The cutoå value of 5 mg l ± 1 for CK-MB mass, a method which is more standardized than troponin, agrees with that proposed by the manufacturer and some authors working with other commercial kits [42, 43] . We have demonstrated that the sensitivity of CK-MB mass for the diagnosis of AMI during the ® rst 6 h of precordial pain is higher than troponin I using 0.77 and 1.5 mg l ± 1 as the cutoå values. Other authors [42, 44± 46] have had similar results using other commercial kits. It must be taken into account that although CK-MB has a greater molecular mass than troponin, its intracellular localization is cytoplasmatic, thus favouring its release to the circulation. In contrast, the possible localization of CK-MB in skeletal muscle decreases the speci® city of the test for the diagnosis of coronary ischaemia.
In conclusion, the methods studied are highly speci® c, and show good reliability and practicability for the emergency diagnosis of acute coronary ischaemia. With 120 (l, sample results of the two cardiac markers may be obtain in 16 min. Both markers showed a reliable diagnostic sensitivity for acute myocardial infarction after 6 h of precordial pain. However, we proposed using 0.77 instead oå 1.5 mg l ± 1 as the cutoå value for troponin I.
